Equities Analysts Set Expectations for Zoetis Inc.’s Q3 2016 Earnings (ZTS)
Zoetis Inc. (NYSE:ZTS) – Equities research analysts at Jefferies Group issued their Q3 2016 earnings estimates for shares of Zoetis in a report released on Thursday. Jefferies Group analyst J. Holford anticipates that the brokerage will post earnings per share of $0.46 for the quarter. Jefferies Group currently has a “Buy” rating and a $60.00 target price on the stock. Jefferies Group also issued estimates for Zoetis’ FY2016 earnings at $1.90 EPS.
Other equities analysts also recently issued research reports about the company. Argus raised their target price on Zoetis from $54.00 to $58.00 and gave the company a “below average” rating in a research report on Friday, September 9th. Credit Suisse Group AG reaffirmed an “outperform” rating and issued a $60.00 price target on shares of Zoetis in a report on Tuesday, August 23rd. Zacks Investment Research cut Zoetis from a “hold” rating to a “sell” rating in a report on Thursday. Stifel Nicolaus reaffirmed a “buy” rating and issued a $58.00 price target on shares of Zoetis in a report on Wednesday. Finally, Barclays PLC increased their price target on Zoetis from $45.00 to $49.00 and gave the company an “equal weight” rating in a report on Thursday, August 4th. Three analysts have rated the stock with a sell rating, two have given a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Zoetis has an average rating of “Buy” and a consensus price target of $55.27.
Zoetis (NYSE:ZTS) traded down 0.98% during trading on Friday, reaching $50.52. The company had a trading volume of 607,749 shares. Zoetis has a 52 week low of $38.26 and a 52 week high of $53.14. The firm has a market capitalization of $25.01 billion, a price-to-earnings ratio of 39.35 and a beta of 1.01. The company’s 50-day moving average is $51.26 and its 200 day moving average is $48.95.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/14/equities-analysts-set-expectations-for-zoetis-inc-s-q3-2016-earnings-zts.html
Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Wednesday, August 3rd. The company reported $0.49 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.44 by $0.05. Zoetis had a return on equity of 77.58% and a net margin of 13.15%. The company earned $1.20 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same quarter in the previous year, the business earned $0.43 EPS. Zoetis’s revenue was up 2.8% compared to the same quarter last year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. NEXT Financial Group Inc raised its position in Zoetis by 9.5% in the second quarter. NEXT Financial Group Inc now owns 2,136 shares of the company’s stock worth $101,000 after buying an additional 186 shares during the period. Kelly Lawrence W & Associates Inc. CA raised its position in Zoetis by 113.4% in the second quarter. Kelly Lawrence W & Associates Inc. CA now owns 2,446 shares of the company’s stock worth $116,000 after buying an additional 1,300 shares during the period. NN Investment Partners Holdings N.V. bought a new position in Zoetis during the first quarter worth about $118,000. Northwestern Mutual Wealth Management Co. raised its position in Zoetis by 22.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,566 shares of the company’s stock worth $121,000 after buying an additional 476 shares during the period. Finally, Glenmede Trust Co. NA raised its position in Zoetis by 4.4% in the second quarter. Glenmede Trust Co. NA now owns 2,950 shares of the company’s stock worth $139,000 after buying an additional 124 shares during the period. Hedge funds and other institutional investors own 93.12% of the company’s stock.
In related news, Director Michael B. Mccallister bought 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 6th. The stock was purchased at an average cost of $51.34 per share, for a total transaction of $102,680.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Andrew Fenton sold 13,870 shares of Zoetis stock in a transaction on Friday, September 2nd. The shares were sold at an average price of $51.25, for a total value of $710,837.50. Following the completion of the transaction, the insider now owns 17,719 shares of the company’s stock, valued at $908,098.75. The disclosure for this sale can be found here. 0.05% of the stock is owned by corporate insiders.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Thursday, November 3rd will be paid a $0.095 dividend. The ex-dividend date of this dividend is Tuesday, November 1st. This represents a $0.38 dividend on an annualized basis and a dividend yield of 0.74%. Zoetis’s payout ratio is presently 29.69%.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.